Dsrna targeting LPA and use thereof
By designing double-stranded ribonucleic acid (dsRNA) targeting the LPA gene, the problem of difficulty in reducing Lp(a) levels in the prior art is solved, and effective reduction of cardiovascular risk is achieved.
Patent Information
- Application Number
- PCT/CN2024/096731
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-25
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
The prior art lacks targeted therapeutic drugs to reduce the level of Lp(a) in serum, leading to the risk of adverse cardiovascular events, and Lp(a) proteins are difficult to become direct targets for small and large molecules.
A double-stranded ribonucleic acid (dsRNA) targeting the LPA gene was designed to form the sense and antisense strands of the double-stranded region, and the specific sequence and modification methods to ensure that it can efficiently reduce Lp(a) expression, thereby reducing the heart. Vascular risk.
By targeting the dsRNA of the LPA gene, the serum level is significantly reduced and the risk of cardiovascular events is reduced, providing a targeted treatment plan to reduce Lp(a).
Smart Images

Figure PCTCN2024096731-FTAPPB-I100001 
Figure PCTCN2024096731-FTAPPB-I100002 
Figure PCTCN2024096731-FTAPPB-I100003
Abstract
Description
A dsRNA targeting LPA and its application
[0001] The present disclosure claims the priority of Chinese patent application 202310628559.8 with an application date of May 31, 2023 and the priority of Chinese patent application 202311386740.9 with an application date of October 25, 2023, and the present disclosure cites the full text of the above-mentioned Chinese patent applications. Technical Field
[0002] The present disclosure belongs to the field of biomedicine, and specifically relates to a dsRNA targeting LPA, and its application and preparation method. Background Art
[0003] Lipoprotein (a) (Lp(a)), first discovered by Norwegian geneticist Berg in 1963, was identified as a unique lipoprotein (Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963;59:369–82). Lp(a) is composed of two components: lipids and proteins. The lipid component primarily consists of LDL-like particles located in the core; the protein component is located peripherally and is composed of apolipoprotein (a) (apo(a)) and apoB100 linked by disulfide bonds. Apo(a) is primarily expressed in the liver, with expression limited to humans and non-human primates. It is characterized by the presence of three internal disulfide-bonded tricyclic domains (kringles). In the human lineage, the expansion and differentiation of the Kringle IV domain in apo(a) resulted in ten different types of KIV domains, among which the further expansion of Kringle IV type 2 (KIV-2) produced multi-allelic (1 to 40 copies) intra-copy number variation (CNV), while the other Kringle IV encoding domains (KIV-1 and KIV-3 to KIV-10) only exist as single copies (Schmidt K, Noureen A, Kronenberg F, et al. Structure, Function, and Genetics of Lipoprotein(a)[J]. Journal of Lipid Research, 2016, 57(8):1339.). All Kringles are transcribed and translated, so KIV-2 CNV leads to size polymorphism of the encoded apo(a), whose expression is inversely proportional to the number of KIV-2 domains present. When the number of KIV-2 copies is low, the level of Lp(a) in plasma will increase significantly.
[0004] Patients with elevated Lp(a) have a 2-3 times higher risk of cardiovascular events than the normal population, causing cardiovascular diseases including atherosclerotic cardiovascular disease, lower limb artery disease, aortic valve stenosis, etc. (EnAs EA, Varkey B, Dharmarajan TS, et al. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction[J]. Indian Heart Journal, 2019, 71(2).). Lp(a) may contribute to adverse atherosclerotic cardiovascular disease (ASCVD) through two mechanisms: First, because apo(a) has been shown to inhibit fibrinolysis in vitro, it may promote thrombosis at plaque rupture or turbulence at vascular stenosis, leading to vascular obstruction or thrombosis; second, LDL-like particles can promote intimal cholesterol deposition, inflammation, or oxidized phospholipids, leading to atherosclerotic stenosis or aortic valve stenosis (Albert Youngwoo Jang, Seung Hwan Han, Il Suk Sohn, et al. Lipoprotein(a) and Cardiovascular Diseases[J]. Circulation Journal, 2020, 84:867–874). However, even very high levels of Lp(a) contain cholesterol levels below the traditional LDL cutoff, and therefore, this portion of LDL-like particles may be less pathogenic.
[0005] The 2016 Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults define abnormal Lp(a) levels as >30 mg / dL. Based on this standard, approximately 30% of patients with prior cardiovascular events in China have abnormal Lp(a). In 2019, the US National Lipid Association recommended an elevated Lp(a) level of ≥50 mg / dL. Using this standard, 20% of the global population has elevated Lp(a). Despite the common nature of elevated Lp(a), targeted therapeutics are lacking, and no drugs targeting Lp(a) have been approved for clinical use. The Lp(a) protein, structurally similar to many lipoproteins, is a difficult target for both small and large molecule drugs. However, the mRNA transcribed from the Lp(a) gene is highly specific, allowing for post-transcriptional degradation of the mRNA through siRNA, thereby inhibiting Lp(a) expression. Therefore, siRNA targeting the apo(a) gene (LPA) has been designed to attenuate its expression, thereby reducing serum Lp(a) levels and, consequently, cardiovascular adverse events.
[0006] Summary of the Invention
[0007] The present disclosure provides a double-stranded RNA, which comprises a sense strand and an antisense strand; the sense strand and the antisense strand form a double-stranded region (preferably the sense strand and the antisense strand are reverse complementary); the double-stranded RNA targets the LPA gene or its expression product.
[0008] In some embodiments, the dsRNA comprises at least one modified nucleotide in the sense strand and / or the antisense strand.
[0009] The present disclosure provides a double-stranded ribonucleic acid (dsRNA) targeting LPA, which comprises a sense strand and an antisense strand forming a double-stranded region, wherein:
[0010] The naked nucleotide sequence of the sense strand comprises at least 17 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 1 by no more than 3 nucleotides; and
[0011] The naked nucleotide sequence of the antisense strand comprises at least 19 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 2 by no more than 3 nucleotides; wherein, in the direction from the 5' end to the 3' end,
[0012] The nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides;
[0013] The nucleotides at positions 2 and 14 of the antisense strand are 2'-fluoro-modified nucleotides, the nucleotides at positions 4, 6, 10, 12, 16 and 18 are independently 2'-methoxy or 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides;
[0014] The number of 2'-fluoro-modified nucleotides in the antisense strand is 2-7 (eg, 2, 3, 4, 5, 6, 7).
[0015] In some embodiments, the naked nucleotide sequence of the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO: 1, and the naked nucleotide sequence of the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO: 2; wherein, in the direction from 5' to 3',
[0016] The nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides;
[0017] The nucleotides at positions 2 and 14 of the antisense strand are 2'-fluoro-modified nucleotides, the nucleotides at positions 4, 6, 10, 12, 16 and 18 are independently 2'-methoxy or 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides;
[0018] The number of 2'-fluoro-modified nucleotides in the antisense strand is 2-7 (eg, 2, 3, 4, 5, 6, 7).
[0019] In some embodiments, the sense and antisense strands:
[0020] The positive strand contains 5'-GCUCCUUAUUGUUAUACGA-3',
[0021] The antisense strand contains 5'-UCGUAUAACAAUAAGGAGCUG-3'.
[0022] In other embodiments, the sense and antisense strands:
[0023] The naked nucleotide sequence of the positive strand is 5'-GCUCCUUAUUGUUAUACGA-3',
[0024] The naked nucleotide sequence of the antisense strand is 5′-UCGUAUAACAAUAAGGAGCUG-3′;
[0025] Naked sequence refers to a nucleotide sequence that has not been modified.
[0026] In some embodiments, the 7th nucleotide from the 5' end of the antisense strand of the dsRNA is a modified nucleotide, wherein the modified nucleotide is a 2'-methoxy modified nucleotide.
[0027] In some embodiments, the nucleotide at position 7 at the 5' end of the antisense strand of the dsRNA is a modified nucleotide, wherein the modified nucleotide comprises a chemical modification represented by formula (I), (I-1), or (I-2), or a pharmaceutically acceptable salt thereof:
[0028] Wherein, B is the same as the base of the antisense strand when the 7th nucleotide at its 5' end is not modified; in some specific embodiments, B is adenine.
[0029] In some embodiments, the chemical modification represented by formula (I'), (I'-1), (I'-2) is selected from:
[0030] Wherein: M is O or S; wherein: B is the same as the base of the antisense strand when the 7th nucleotide at its 5' end is not modified; in some specific embodiments, B is adenine.
[0031] In some specific embodiments, M is S. In some specific embodiments, M is O.
[0032] In some embodiments, the first nucleotide at the 5' end of the antisense strand of the dsRNA is a modified nucleotide, wherein the modified nucleotide is a 2'-methoxy modified nucleotide.
[0033] In some embodiments, the first nucleotide at the 5' end of the antisense strand of the dsRNA is a modified nucleotide, wherein the modified nucleotide is a chemically modified nucleotide represented by formula (IV):
[0034] in,
[0035] R A1 、R A2 are each independently selected from hydrogen or deuterium;
[0036] M1 and M2 are each independently selected from -SH or -OH;
[0037] B is selected from base, hydrogen, deuterium; R A3 R is selected from hydrogen, deuterium, hydroxyl, halogen, alkyl (e.g., C1, C2, C3, C4, C5, C6 alkyl, including but not limited to methyl, ethyl, isopropyl), alkoxy (e.g., C1 alkoxy, C2 alkoxy, C3 alkoxy, C4 alkoxy, C5 alkoxy, C6 alkoxy, including but not limited to methoxy, ethoxy, propoxy, isopropoxy), wherein each of the hydroxyl, alkyl, and alkoxy groups is optionally substituted with one or more deuterium groups; A4 Selected from hydrogen, deuterium, alkyl (e.g., C1, C2, C3, C4, C5, C6 alkyl, including but not limited to methyl, ethyl, isopropyl), each of which is optionally substituted with one or more deuterium; provided that formula (IV) contains at least one deuterium.
[0038] In some embodiments, R A3 Selected from hydrogen and deuterium.
[0039] In other embodiments, R A3 is selected from halogen (such as fluorine, chlorine, bromine).
[0040] In other embodiments, R A3 Selected from alkyl groups (e.g., C1, C2, C3, C4, C5, C6 alkyl groups, including but not limited to methyl, ethyl, isopropyl), each of which is optionally substituted with one or more deuterium groups.
[0041] In other embodiments, R A3Selected from alkoxy (e.g., C1 alkoxy, C2 alkoxy, C3 alkoxy, C4 alkoxy, C5 alkoxy, C6 alkoxy, including but not limited to methoxy, ethoxy, propoxy, isopropoxy), each of which is optionally substituted with one or more deuterium groups.
[0042] In some embodiments, the 5' terminal chemical modification represented by formula (IV) is:
[0043] Among them, R A5 、R A6 、R A7 are each independently selected from hydrogen or deuterium;
[0044] R A1 、R A2 , M1, M2, and B are as defined in formula (IV); provided that formula (IV-1) contains at least one deuterium.
[0045] In some embodiments, R A5 、R A6 、R A7 All deuterium.
[0046] In some embodiments, R A5 is deuterium, R A6 、R A7 It's hydrogen.
[0047] In some embodiments, R A5 、R A6 is deuterium, R A7 It's hydrogen.
[0048] In some embodiments, R A1 is hydrogen, R A2 It's deuterium.
[0049] In some embodiments, R A1 and R A2 It's deuterium.
[0050] In some embodiments, R A1 and R A2 It's hydrogen.
[0051] In some embodiments, the 5' terminal chemical modification represented by formula (IV) is selected from: B is selected from a base or hydrogen.
[0052] In some embodiments, B is selected from a base; in some specific embodiments, B is selected from adenine, guanine, cytosine, uracil, or thymine.
[0053] In some specific embodiments, B is the base at the corresponding position of the modified nucleotide in the antisense strand.
[0054] In some specific embodiments, B is selected from uracil.
[0055] In some embodiments, the 5' terminal chemical modification represented by formula (IV) is selected from: and structures in which uracil is replaced by adenine, guanine, cytosine, or thymine.
[0056] In some embodiments, in the direction from the 5' end to the 3' end, the first nucleotide at the 5' end of the antisense strand of the dsRNA is the 5' end chemically modified nucleotide shown in formula (IV). In some specific embodiments, the 5' end chemically modified nucleotide shown in formula (IV) is The B is the base corresponding to the first nucleotide at the 5' end of the antisense strand.
[0057] In some embodiments, the first nucleotide at the 5' end of the antisense strand of the dsRNA is a modified nucleotide, wherein the modified nucleotide is a chemically modified nucleotide represented by formula (II):
[0058] Wherein, B represents the base corresponding to the first nucleotide at the 5' end of the antisense strand. In some specific embodiments, B represents uracil.
[0059] In some embodiments, the antisense strand is at least partially reverse complementary to the target sequence to mediate RNA interference. In some embodiments, there are no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 mismatch between the antisense strand and the target sequence; in some embodiments, the antisense strand is completely reverse complementary to the target sequence.
[0060] In some embodiments, the sense strand and the antisense strand are at least partially reverse complementary to form a double-stranded region; in some embodiments, there are no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 mismatch between the sense strand and the antisense strand; in some embodiments, the sense strand and the antisense strand are completely reverse complementary.
[0061] In some embodiments, the sense and antisense strands each independently have 16 to 35, 16 to 34, 17 to 34, 17 to 33, 18 to 33, 18 to 32, 18 to 31, 18 to 30, 18 to 29, 18 to 28, 18 to 27, 18 to 26, 18 to 25, 18 to 24, 18 to 23, 19 to 25, 19 to 24, or 19 to 23 nucleotides.
[0062] In some specific embodiments, the sense strand and antisense strand are each independently 19, 20, 21, 22, or 23 nucleotides in length.
[0063] In some embodiments, the sense strand and antisense strand are the same or different in length, with the sense strand being 19-23 nucleotides in length and the antisense strand being 19-26 nucleotides in length. In some embodiments, the ratio of the length of the sense strand to the antisense strand can be 19 / 20, 19 / 21, 19 / 22, 19 / 23, 19 / 24, 19 / 25, 19 / 26, 20 / 20, 20 / 21, 20 / 22, 20 / 23, 20 / 24, 20 / 25, 20 / 26, 21 / 20, 21 / 21, 21 / 22, 21 / 23, 21 / 24, 21 / 25, 21 / 26, 22 / 20, 22 / 21, 22 / 22, 22 / 23, 22 / 24, 22 / 25, 22 / 26, 23 / 20, 23 / 21, 23 / 22, 23 / 23, 23 / 24, 23 / 25, or 23 / 26. In some embodiments, the length ratio of the sense strand to the antisense strand is 19 / 21, 21 / 23, or 23 / 25. In some embodiments, the length ratio of the sense strand to the antisense strand is 19 / 21.
[0064] In some embodiments, the dsRNA comprises one or two blunt ends.
[0065] In some embodiments, the dsRNA comprises an overhang of 1 to 4 unpaired nucleotides, eg, 1, 2, 3, 4.
[0066] In some embodiments, the dsRNA comprises an overhang at the 3' end of the antisense strand.
[0067] In some embodiments, the sense strand of the dsRNA contains or is a nucleotide sequence as shown in the following formula: 5'-N a N a N a N a N a N a N b N b Nb N a N a N a N a N a N a N a N a N a N a -3'; where N a 2'-methoxy modified nucleotides, N b It is a 2'-fluoro modified nucleotide.
[0068] In some embodiments, the antisense strand of the dsRNA comprises or is a nucleotide sequence as shown in the following formula:
[0069] 5'-N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a 'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3',
[0070] Wherein each X' is independently N a ' or N b ';N a ' is a 2'-methoxy modified nucleotide, N b ' is a 2'-fluoro-modified nucleotide.
[0071] In some embodiments, the antisense strand of the dsRNA comprises or is a nucleotide sequence as shown in the following formula:
[0072] 5'-N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b’N a ’N a ’N a ’N a ’N a ’-3’,
[0073] 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’,
[0074] 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’,
[0075] 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’Nb ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’,
[0076] 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0077] 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0078] 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’Na ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0079] 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0080] 5’-N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’,
[0081] 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’Na 'N a 'N a 'N a 'N a 'N a 'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a '-3',
[0082] 5'-N a 'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a '-3',
[0083] 5'-N a 'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a '-3',
[0084] Among them, N a ' is a 2'-methoxy modified nucleotide, N b ' is a 2'-fluoro-modified nucleotide.
[0085] In some embodiments, the antisense strand of the dsRNA comprises or is a nucleotide sequence as shown in the following formula: 5'-N a 'N b 'N a 'X'N a 'X'W'N a 'N a 'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3', where each X' is independently N a ' or N b ';N a ' is a 2'-methoxy modified nucleotide, N b ' is a 2'-fluoro modified nucleotide, and W' represents a nucleotide comprising a chemical modification represented by formula (I), (I-1), or (I-2) or a pharmaceutically acceptable salt thereof.
[0086] In some embodiments, the antisense strand of the dsRNA comprises or is a nucleotide sequence as shown in the following formula:
[0087] 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a '-3',
[0088] 5'-N a 'N b 'N a 'N b 'N a 'N b 'W'N a 'N a 'N b’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’,
[0089] 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’,
[0090] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’,
[0091] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’Na ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0092] 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0093] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0094] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’,
[0095] 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’,
[0096] 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’,
[0097] 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N a ’Na 'N a 'N a 'N a 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a '-3',
[0098] Among them, N a ' is a 2'-methoxy modified nucleotide, N b ' is a 2'-fluoro modified nucleotide; W' represents a nucleotide comprising a chemical modification represented by formula (I), (I-1), (I-2) or a pharmaceutically acceptable salt thereof.
[0099] In some embodiments, the antisense strand of the dsRNA comprises or is a nucleotide sequence as shown in the following formula: 5'-V'N b 'N a 'X'N a 'X'N a 'N a 'N a 'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3', where each X' is independently N a ' or N b ';N a ' is a 2'-methoxy modified nucleotide, N b ' represents a 2'-fluoro-modified nucleotide; V' represents a chemically modified nucleotide represented by formula (II).
[0100] In some embodiments, the antisense strand of the dsRNA comprises or is a nucleotide sequence as shown in the following formula:
[0101] 5'-V'N b 'N a 'N a 'N a 'N b 'N a 'N a 'N a 'N a 'N a 'N b 'Na 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a '-3',
[0102] 5'-V'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N a 'N b 'N a 'N b 'N a 'N a 'N a 'N a 'N a 'N a 'N a '-3';
[0103] Among them, N a ' is a 2'-methoxy modified nucleotide, N b ' represents a 2'-fluoro-modified nucleotide; V' represents a chemically modified nucleotide represented by formula (II).
[0104] In some embodiments, the chemical modification represented by formula (I), (I-1), (I-2) or a pharmaceutically acceptable salt thereof is selected from:
[0105] Wherein: B represents the 7th base at the 5' end of the antisense strand. In some specific embodiments, B is adenine.
[0106] In some embodiments, the chemical modification represented by formula (I'), (I'-1), (I'-2) or a pharmaceutically acceptable salt thereof is selected from:
[0107] Wherein: M is O or S; Wherein: B represents the 7th base at the 5' end of the antisense strand, and in some specific embodiments, B is adenine.
[0108] In some embodiments, M is S. In some specific embodiments, M is O.
[0109] In some embodiments, the chemically modified nucleotide represented by formula (II) is selected from:
[0110] Wherein, B represents the base corresponding to the first nucleotide at the 5' end of the antisense strand. In some specific embodiments, B represents uracil.
[0111] In some embodiments, the chemically modified nucleotide represented by formula (II) is selected from:
[0112] Wherein, B represents the base corresponding to the first nucleotide at the 5' end of the antisense strand. In some specific embodiments, B represents uracil.
[0113] In some embodiments, at least one phosphodiester group in the sense strand and / or antisense strand of the dsRNA is a phosphodiester group having a modified group.
[0114] In some embodiments, at least one phosphodiester group in the sense strand and / or antisense strand of the dsRNA is a phosphorothioate diester group.
[0115] In some embodiments, the phosphorothioate diester group is present in at least one of the following positions:
[0116] between the first and second nucleotides at the 5' end of the sense strand;
[0117] between the second and third nucleotides at the 5' end of the sense strand;
[0118] between the first and second nucleotides at the 3' end of the sense strand;
[0119] between the first and second nucleotides at the 5' end of the antisense strand;
[0120] between the second and third nucleotides at the 5' end of the antisense strand;
[0121] between the first and second nucleotides at the 3' end of the antisense strand; and
[0122] between the second and third nucleotides at the 3' end of the antisense strand.
[0123] In some embodiments, the sense strand and / or antisense strand includes multiple phosphorothioate diester groups, wherein the phosphorothioate diester groups are present in:
[0124] between the first nucleotide and the second nucleotide at the 5' end of the sense strand; and
[0125] between the second and third nucleotides at the 5' end of the sense strand; and
[0126] between the first and second nucleotides at the 3' end of the sense strand; and
[0127] between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; and
[0128] between the second and third nucleotides from the 5' end of the antisense strand; and
[0129] between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and
[0130] between the second and third nucleotides at the 3' end of the antisense strand.
[0131] In some embodiments, the sense strand and / or antisense strand includes multiple phosphorothioate diester groups, wherein the phosphorothioate diester groups are present in:
[0132] between the first nucleotide and the second nucleotide at the 5' end of the sense strand; and
[0133] between the second and third nucleotides at the 5' end of the sense strand; and
[0134] between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; and
[0135] between the second and third nucleotides from the 5' end of the antisense strand; and
[0136] between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and
[0137] between the second and third nucleotides at the 3' end of the antisense strand.
[0138] In some embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in any one of SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22 to SEQ ID NO:33, and SEQ ID NO:35.
[0139] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:16.
[0140] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:20.
[0141] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:22.
[0142] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:23.
[0143] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:24.
[0144] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:25.
[0145] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:26.
[0146] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:27.
[0147] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:28.
[0148] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:29.
[0149] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:30.
[0150] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:31.
[0151] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:32.
[0152] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:33.
[0153] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:35.
[0154] In some embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in any one of SEQ ID NO:9 to SEQ ID NO:20, SEQ ID NO:33 to SEQ ID NO:35.
[0155] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:9.
[0156] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:10.
[0157] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:11.
[0158] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:12.
[0159] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:13.
[0160] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:14.
[0161] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:15.
[0162] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:16.
[0163] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:17.
[0164] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:18.
[0165] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:19.
[0166] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:20.
[0167] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:33.
[0168] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:34.
[0169] In some specific embodiments, the sense strand of the dsRNA comprises or is selected from the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises or is selected from the nucleotide sequence shown in SEQ ID NO:35.
[0170] In some embodiments, the dsRNA is:
[0171] The nucleotide sequence of the sense strand comprises SEQ ID NO:6, and the nucleotide sequence of the antisense strand comprises SEQ ID NO:16.
[0172] In some embodiments, the dsRNA has a sense strand nucleotide sequence as shown in SEQ ID NO: 6, and an antisense strand nucleotide sequence as shown in SEQ ID NO: 16. The present disclosure also provides a dsRNA conjugate comprising any one of the above dsRNAs and a targeting ligand linked to the dsRNA.
[0173] In some embodiments, the dsRNA and the targeting ligand are covalently or non-covalently linked.
[0174] In some embodiments, the targeting ligand targets the liver. In some embodiments, the targeting ligand binds to the asialoglycoprotein receptor (ASGPR). In some embodiments, the targeting ligand comprises a galactose cluster or a galactose derivative cluster selected from N-acetyl-galactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, N-n-butyrylgalactosamine, or N-isobutyrylgalactosamine.
[0175] In some embodiments, the targeting ligand is linked to the 3' end of the sense strand of the dsRNA.
[0176] In some embodiments, the targeting ligand is linked to the dsRNA terminus via a phosphodiester group, a phosphorothioate diester group, or a phosphonic acid group. In some embodiments, the targeting ligand is linked to the dsRNA terminus via a phosphodiester group.
[0177] In some embodiments, the targeting ligand is indirectly linked to the dsRNA terminus via a phosphodiester group, a phosphorothioate diester group, or a phosphonic acid group. In some embodiments, the targeting ligand is indirectly linked to the dsRNA terminus via a phosphodiester group.
[0178] In some embodiments, the targeting ligand is directly linked to the end of the dsRNA via a phosphodiester group, a phosphorothioate diester group, or a phosphonic acid group. In some embodiments, the targeting ligand is directly linked to the end of the dsRNA via a phosphodiester group.
[0179] In some embodiments, the targeting ligand is directly linked to the end of the dsRNA sense strand via a phosphodiester group or a phosphorothioate diester group. In some embodiments, the targeting ligand is linked to the end of the dsRNA sense strand via a phosphodiester group.
[0180] In some embodiments, the targeting ligand is directly linked to the 3' end of the sense strand of the dsRNA via a phosphodiester group or a phosphorothioate diester group. In some embodiments, the targeting ligand is directly linked to the 3' end of the sense strand of the dsRNA via a phosphodiester group.
[0181] In some embodiments, to facilitate dsRNA entry into cells, lipophilic groups such as cholesterol can be introduced at the terminus of the dsRNA sense strand. Lipophilic groups can covalently bind to small interfering nucleic acids, such as by introducing cholesterol, lipoproteins, or vitamin E at the terminus, thereby facilitating interaction with intracellular mRNA through the lipid bilayer cell membrane. dsRNA can also be modified with non-covalent bonds, such as by hydrophobic or ionic bonds to phospholipid molecules, polypeptides, or cationic polymers to increase stability and biological activity.
[0182] In some embodiments, the targeting portion of a targeting ligand is composed of one or more targeting groups or targeting moieties that assist in directing the delivery of the therapeutic agent to which it is attached to the desired target location. In some cases, the targeting moiety can bind to cells or cell receptors and initiate endocytosis to promote the entry of the therapeutic agent into the cell. The targeting moiety can include a compound with affinity for a cell receptor or a cell surface molecule or antibody. Various targeting ligands containing a targeting moiety can be linked to therapeutic agents and other compounds to target the agent to cells and specific cell receptors.
[0183] In some embodiments, the types of targeting moieties include carbohydrates, cholesterol and cholesterol groups or steroids. Targeting moieties that can bind to cell receptors include sugars such as galactose, galactose derivatives (e.g., N-acetyl-galactosamine, N-trifluoroacetylgalactosamine, N-propionylgalactosamine, N-n-butyrylgalactosamine, N-isobutyrylgalactosamine), mannose and mannose derivatives).
[0184] Targeting moieties that are known to bind to the asialoglycoprotein receptor (ASGPR) are particularly useful for directing the delivery of oligomeric compounds to the liver. The asialoglycoprotein receptor is abundantly expressed on liver cells (hepatocytes). Cell receptor targeting moieties that target the ASCPR include galactose and galactose derivatives. Specifically, clusters of galactose derivatives, including clusters consisting of 2, 3, 4, or more than 4 N-acetyl-galactosamine (GalNAc or NAG) can promote the uptake of certain compounds in hepatocytes. The GalNAc clusters conjugated to the oligomeric compound are used to direct the composition to the liver, where the N-acetyl-galactosamine sugar can bind to the asialoglycoprotein receptor on the surface of liver cells. Binding of the asialoglycoprotein receptor is believed to initiate receptor-mediated endocytosis, thereby promoting the entry of the compound into the cell interior.
[0185] In some embodiments, a targeting ligand can include 2, 3, 4, or more than 4 targeting moieties.
[0186] In some embodiments, each targeting moiety independently comprises a galactosamine derivative, which is N-acetyl-galactosamine. Other sugars that can be used as targeting moieties and have affinity for asialoglycoprotein receptors can be selected from galactose, galactosamine, N-formyl-galactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butyryl-galactosamine, and N-isobutyryl-galactosamine.
[0187] In some embodiments, the targeting ligands of the present disclosure include N-acetylgalactosamine as a targeting moiety.
[0188] In some embodiments, the targeting ligand comprises three terminal galactosamines or galactosamine derivatives (such as N-acetyl-galactosamine), each of which has affinity for sialoglycoprotein receptors. In some embodiments, the targeting ligand comprises three terminal N-acetyl-galactosamines (GalNAc or NAG) as targeting moieties.
[0189] In some embodiments, the targeting ligand comprises four terminal galactosamines or galactosamine derivatives (such as N-acetyl-galactosamine), each of which has affinity for the asialoglycoprotein receptor. In some embodiments, the targeting ligand comprises four terminal N-acetyl-galactosamines (GalNAc or NAG) as targeting moieties.
[0190] Terms commonly used in the art when referring to the three terminal N-acetyl-galactosamines include tri-antennary, tri-valent, and trimer.
[0191] Terms commonly used in the art when referring to the four terminal N-acetyl-galactosamines include tetra-antennary, tetra-valent, and tetramer.
[0192] In some embodiments, the targeting ligand provided by the present disclosure is a compound represented by formula (III-1) or a pharmaceutically acceptable salt thereof,
[0193] In some embodiments, the targeting ligand provided by the present disclosure is a compound represented by formula (III-2) or a pharmaceutically acceptable salt thereof,
[0194] In some embodiments, the N-acetyl-galactosamine moiety in the above targeting ligands can be replaced with N-trifluoroacetylgalactosamine, N-propionylgalactosamine, N-n-butyrylgalactosamine, or N-isobutyrylgalactosamine.
[0195] In some embodiments, the nucleotide sequence of the sense strand of the dsRNA conjugate comprises or is selected from SEQ ID NO: 3, and the nucleotide sequence of the antisense strand comprises or is selected from any one of SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 22 to SEQ ID NO: 33, and SEQ ID NO: 35.
[0196] In some embodiments, the nucleotide sequence of the sense strand of the dsRNA conjugate comprises or is selected from SEQ ID NO: 4, and the nucleotide sequence of the antisense strand comprises or is selected from any one of SEQ ID NO: 9 to SEQ ID NO: 20, and SEQ ID NO: 33 to SEQ ID NO: 35.
[0197] In some embodiments, the nucleotide sequence of the sense strand of the dsRNA conjugate comprises or is selected from SEQ ID NO: 5, and the nucleotide sequence of the antisense strand comprises or is selected from any one of SEQ ID NO: 16, SEQ ID NO: 20, and SEQ ID NO: 33.
[0198] In some embodiments, the dsRNA conjugate is:
[0199] The nucleotide sequence of the sense strand comprises SEQ ID NO:3, and the nucleotide sequence of the antisense strand comprises SEQ ID NO:16.
[0200] In some embodiments, the dsRNA conjugate is:
[0201] The nucleotide sequence of the sense strand is shown in SEQ ID NO: 3, and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 16.
[0202] In some embodiments, the dsRNA conjugate is the following structure or a pharmaceutically acceptable salt thereof:
[0203] Among them, Af = adenine 2'-F ribonucleoside; Cf = cytosine 2'-F ribonucleoside; Uf = uracil 2'-F ribonucleoside; Gf = guanine 2'-F ribonucleoside; Am = adenine 2'-OMe ribonucleoside; Cm = cytosine 2'-OMe ribonucleoside; Gm = guanine 2'-OMe ribonucleoside; Um = uracil 2'-OMe ribonucleoside.
[0204] represents a phosphorothioate diester group; represents a phosphodiester group;
[0205] NAG0052' indicates
[0206] In some embodiments, the dsRNA conjugate is the following structure or a pharmaceutically acceptable salt thereof:
[0207] Among them, Af = adenine 2'-F ribonucleoside; Cf = cytosine 2'-F ribonucleoside; Uf = uracil 2'-F ribonucleoside; Gf = guanine 2'-F ribonucleoside; Am = adenine 2'-OMe ribonucleoside; Cm = cytosine 2'-OMe ribonucleoside; Gm = guanine 2'-OMe ribonucleoside; Um = uracil 2'-OMe ribonucleoside.
[0208] represents the anionic form of the phosphorothioate diester group; represents the anionic form of the phosphodiester group;
[0209] NAG0052' indicates
[0210] In some embodiments, the pharmaceutically acceptable salt may be a conventional salt in the art, including but not limited to sodium salt, potassium salt, ammonium salt, amine salt, and the like.
[0211] In some embodiments, the dsRNA conjugate is selected from TJR100422, TJR100423, TJR100424, TJR100425, TJR100426, TJR100427, TJR100428, TJR100429, TJR100430, TJR100431, TJR100432, TJR100800, TJR100801, TJR100802, TJR100803, TJR100804, TJR100805, TJR100806, TJR100807, TJR100808, TJR100809, TJR100810, TJR100811, TJR100812, TJR100813, TJR100814, TJR100815, TJR100816, TJR100817, TJR100818, TJR100819, TJR100820, TJR100821, TJR100822 05, any one of TJR100806, TJR100807, TJR100808, TJR100809, TJR100810, TJR100811, TJR101079, TJR101080, TJR101081, TJR101082, TJR101083, TJR101085, TJR101086, TJR101087, TJR101088, TJR101084, TJR102134, TJR102136.
[0212] In some embodiments, the dsRNA conjugate is TJR101079, which has the structure:
[0213] Among them, Af = adenine 2'-F ribonucleoside; Cf = cytosine 2'-F ribonucleoside; Uf = uracil 2'-F ribonucleoside; Gf = guanine 2'-F ribonucleoside; Am = adenine 2'-OMe ribonucleoside; Cm = cytosine 2'-OMe ribonucleoside; Gm = guanine 2'-OMe ribonucleoside; Um = uracil 2'-OMe ribonucleoside.
[0214] represents the anionic form of the phosphorothioate diester group; represents the anionic form of the phosphodiester group;
[0215] NAG0052' indicates
[0216] Another aspect of the present disclosure provides a composition comprising the dsRNA and / or dsRNA conjugate as claimed in claim 1, and one or more pharmaceutically acceptable excipients, such as carriers, vehicles, diluents, and / or delivery polymers.
[0217] Various delivery systems are known and can be used for the dsRNA and / or dsRNA conjugates of the present disclosure, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis, constructing the nucleic acid as part of a retroviral or other vector.
[0218] Another aspect of the present disclosure provides a use of the above-mentioned dsRNA and / or dsRNA conjugate or a composition thereof in the preparation of a medicament for treating a disease in a subject, which in some embodiments is selected from a liver-related disease.
[0219] Another aspect of the present disclosure provides a method for treating a disease in a subject, comprising administering the above-mentioned dsRNA and / or dsRNA conjugate, or composition to the subject.
[0220] Another aspect of the present disclosure provides a method for inhibiting LPA mRNA expression in a subject, comprising administering the above-mentioned dsRNA and / or dsRNA conjugate, or composition to the subject.
[0221] Another aspect of the present disclosure provides a method for delivering an expression-inhibiting oligomeric compound to the liver in vivo, comprising administering the conjugate and / or composition described above to a subject.
[0222] The dsRNA, dsRNA conjugates, compositions, and methods disclosed herein can reduce the level of a target mRNA in a cell, a cell population, a tissue, or a subject, comprising administering to the subject a therapeutically effective amount of a dsRNA described herein, which is linked to a targeting ligand, thereby inhibiting the expression of the target mRNA in the subject.
[0223] In some embodiments, the subject has been previously identified as having aberrant expression of the target gene in the targeted cells or tissues.
[0224] The subject described in the present disclosure refers to a subject suffering from a disease or disorder that would benefit from reduction or inhibition of target mRNA expression.
[0225] Delivery can be by local administration (e.g., direct injection, implantation, or topical administration), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal, and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration.
[0226] In alternative embodiments, the pharmaceutical compositions provided herein can be administered by injection, for example, intravenously, intramuscularly, intradermally, subcutaneously, intraduodenally, or intraperitoneally.
[0227] In an alternative embodiment, after the targeting ligand is linked to the dsRNA to form a conjugate, the conjugate can be packaged in a kit.
[0228] In another aspect, the present disclosure provides a pharmaceutical composition comprising the dsRNA and / or dsRNA conjugate described herein.
[0229] In some embodiments, the pharmaceutical composition may further comprise a pharmaceutically acceptable excipient and / or adjuvant, which may be one or more of various preparations or compounds conventionally used in the art. For example, the pharmaceutically acceptable excipient may include at least one of a pH buffer, a protective agent, and an osmotic pressure regulator.
[0230] In some embodiments, the dsRNA, dsRNA conjugate, or pharmaceutical composition thereof described herein, when contacted with cells expressing the target gene, inhibits the expression of the target gene by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, as measured by, for example, psiCHECK activity screening and luciferase reporter gene assays, other methods such as PCR or branched DNA (bDNA)-based methods, or protein-based methods such as immunofluorescence analysis, e.g., Western Blot or flow cytometry.
[0231] In some embodiments, when a dsRNA, dsRNA conjugate, or pharmaceutical composition thereof is contacted with a cell expressing a target gene, the percentage of target gene mRNA remaining expression caused by the dsRNA, dsRNA conjugate, or pharmaceutical composition thereof is no greater than 99%, no greater than 95%, no greater than 90%, no greater than 85%, no greater than 80%, no greater than 75%, no greater than 70%, no greater than 65%, no greater than 60%, no greater than 55%, no greater than 50%, no greater than 45%, no greater than 40%, no greater than 35%, no greater than 30%, no greater than 25%, no greater than 20%, no greater than 15%, or no greater than 10%, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assays, other methods such as PCR or branched DNA (bDNA)-based methods, or protein-based methods such as immunofluorescence analysis, e.g., Western Blot or flow cytometry.
[0232] In some embodiments, when a dsRNA, dsRNA conjugate, or pharmaceutical composition thereof described herein is contacted with a cell expressing a target gene, the dsRNA, dsRNA conjugate, or pharmaceutical composition thereof, while maintaining target activity, reduces off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as determined by, for example, psiCHECK activity screening and luciferase reporter gene assays, other methods such as PCR or branched DNA (bDNA)-based methods, or protein-based methods such as immunofluorescence analysis, e.g., Western Blot, or flow cytometry.
[0233] In some embodiments, the dsRNA, dsRNA conjugate, or pharmaceutical composition thereof described herein, when contacted with cells expressing a target gene, reduces off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, while reducing target activity by at most 20%, at most 19%, at most 15%, at most 10%, at most 5%, or more than 1%, as measured by, for example, psiCHECK activity screening and luciferase reporter assays, other methods such as PCR or branched DNA (bDNA)-based methods, or protein-based methods such as immunofluorescence analysis, e.g., Western Blot, or flow cytometry.
[0234] In some embodiments, when the dsRNA and / or dsRNA conjugates or pharmaceutical compositions thereof described herein are contacted with cells expressing the target gene, the target gene is detected by, for example, psiCHECK activity screening and luciferase reporter gene assays, other methods such as PCR or branched DNA (bDNA)-based methods, or protein-based methods such as immunofluorescence analysis, for example Western blotting. The dsRNA, dsRNA conjugate, or pharmaceutical composition thereof, increases target activity by at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80%, while reducing off-target activity by at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%, as determined by blot, or flow cytometry.
[0235] In some further specific embodiments, when the dsRNA and / or dsRNA conjugate or pharmaceutical composition thereof described in the present disclosure is contacted with cells expressing the target gene, IC 50 No more than 1nM, no more than 0.9nM, no more than 0.8nM, no more than 0.7nM, no more than 0.6nM, no more than 0.5nM, no more than 0.4nM, no more than 0.3nM, no more than 0.2nM, no more than 0.19nM, no more than 0.18nM, no more than 0.17nM, no more than 0.16nM, no more than 0.15nM, no more than 0.14nM, no more than Higher than 0.13nM, not higher than 0.12nM, not higher than 0.11nM, not higher than 0.10nM, not higher than 0.09nM, not higher than 0.08nM, not higher than 0.07nM, not higher than 0.06nM, not higher than 0.05nM, not higher than 0.04nM, not higher than 0.03nM, not higher than 0.02nM, not higher than 0.01nM, or the range between any two values.
[0236] The present disclosure also provides a cell comprising the dsRNA and / or dsRNA conjugate of the present disclosure.
[0237] The present disclosure also provides a pharmaceutical kit or a test kit comprising one or more containers, wherein the containers independently contain the dsRNA and / or dsRNA conjugate of the present disclosure, or a pharmaceutical composition thereof.
[0238] The present disclosure also provides a method for silencing a target gene or mRNA of a target gene in a cell, the method comprising the step of introducing the dsRNA and / or dsRNA conjugate and / or pharmaceutical composition according to the present disclosure into the cell.
[0239] The present disclosure also provides a method for silencing a target gene or mRNA of a target gene in a cell in vivo or in vitro, the method comprising the step of introducing the dsRNA and / or dsRNA conjugate and / or pharmaceutical composition according to the present disclosure into the cell.
[0240] The present disclosure also provides a method for inhibiting the expression of a target gene or target gene mRNA, which comprises administering an effective amount or effective dose of the dsRNA and / or dsRNA conjugate and / or pharmaceutical composition according to the present disclosure to a subject in need thereof.
[0241] In some embodiments, administration is by a route of administration that includes intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic, intravenous, subcutaneous, cerebrospinal, or a combination thereof.
[0242] In some embodiments, the effective amount or effective dose of the dsRNA and / or dsRNA conjugate and / or pharmaceutical composition is about 0.001 mg / kg body weight to about 200 mg / kg body weight, about 0.01 mg / kg body weight to about 100 mg / kg body weight, or about 0.5 mg / kg body weight to about 50 mg / kg body weight.
[0243] In some embodiments, the target gene is LPA.
[0244] In another aspect, the present disclosure provides a use of the dsRNA and / or dsRNA conjugate or a pharmaceutical composition containing the dsRNA and / or dsRNA conjugate in preparing a medicament.
[0245] In another aspect, the present disclosure provides the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate for use in treating and / or preventing a disease associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a) in a subject. In some embodiments, the disease associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a) is selected from cardiovascular disease. In some embodiments, the cardiovascular disease is selected from ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower extremity arterial disease or aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, heart failure.
[0246] In another aspect, the present disclosure provides the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate for use in treating and / or preventing a disease selected from cardiovascular disease. In some embodiments, the cardiovascular disease is selected from ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower extremity arterial disease or aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, heart failure.
[0247] The present disclosure provides the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate for use in lowering lipoprotein(a) and / or apolipoprotein(a) levels.
[0248] The present disclosure provides use of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate in preparing a medicament for inhibiting the expression of LPA.
[0249] The present disclosure provides the use of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate in the preparation of a medicament for treating and / or preventing a subject's disease associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a). In some embodiments, the disease associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a) is selected from cardiovascular disease. In some embodiments, the cardiovascular disease is selected from ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower extremity arterial disease or aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, heart failure.
[0250] The present disclosure provides the use of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate in the preparation of a medicament for treating and / or preventing a disease, wherein the disease is selected from cardiovascular disease. In some embodiments, the cardiovascular disease is selected from ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower extremity arterial disease or aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, and heart failure.
[0251] The present disclosure provides use of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate in the preparation of a medicament for lowering lipoprotein(a) and / or apolipoprotein(a) levels.
[0252] The present disclosure provides a method for inhibiting LPA expression, comprising administering an effective amount or effective dose of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate to a subject.
[0253] The present disclosure provides a method for treating and / or preventing a disease associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a) in a subject, comprising administering to the subject an effective amount or effective dose of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate. In some embodiments, the disease associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a) is selected from cardiovascular disease; in some embodiments, the cardiovascular disease is selected from ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower limb artery disease or aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, and heart failure.
[0254] The present disclosure provides a method for treating and / or preventing a disease, comprising administering to a subject an effective amount or effective dose of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate, wherein the disease is selected from cardiovascular disease. In some embodiments, the cardiovascular disease is selected from ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower limb artery disease or aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, and heart failure.
[0255] The present disclosure provides a method for reducing lipoprotein (a) and / or apolipoprotein (a) levels, comprising administering to a subject an effective amount or effective dose of the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate.
[0256] The present disclosure provides a method for delivering dsRNA that inhibits LPA expression and / or replication to the liver in vivo, wherein the method comprises administering the aforementioned dsRNA and / or pharmaceutical composition and / or dsRNA conjugate to a subject.
[0257] On the other hand, the present disclosure also provides a method for preparing the dsRNA and / or dsRNA conjugate or pharmaceutical composition of the present disclosure, which comprises: synthesizing the dsRNA and / or dsRNA conjugate or pharmaceutical composition of the present disclosure.
[0258] The present disclosure also provides a dsRNA or dsRNA conjugate, characterized in that one or more bases U in any dsRNA or dsRNA conjugate of the present disclosure are replaced with base T, for example, 1, 2, 3, 3, 5, 6, 7, 8, 9, or 10. In some embodiments, all bases U in the present disclosure can be replaced with base T.
[0259] The pharmaceutically acceptable salts of the compounds described in the present disclosure are selected from inorganic salts or organic salts. The compounds described in the present disclosure can react with acidic or basic substances to form corresponding salts.
[0260] The compounds of the present disclosure may exist in specific geometric or stereoisomeric forms. The present disclosure contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All of these isomers and their mixtures are included within the scope of the present disclosure. The compounds of the present disclosure containing asymmetric carbon atoms can be isolated in optically pure form or in racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
[0261] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is typically accomplished using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate formation from an amine).
[0262] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or or include both and Two configurations. In the chemical structure of the compound disclosed in the present invention, the bond No configuration is specified, i.e. the bond The configuration can be E-type or Z-type, or include both E and Z configurations.
[0263] In the chemical structural formula disclosed herein, One or more of any groups may be attached in accordance with the scope of the invention described herein.
[0264] In the absence of specification of configuration, the compounds and intermediates of the present disclosure may also exist in different tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier.
[0265] The present disclosure also includes isotopically labeled compounds of the present disclosure that are identical to those described herein, but where one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N.15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.
[0266] Compared to non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are encompassed by the present disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced with a deuterium atom, where the deuterium replacement can be partial or complete. Partial deuterium replacement refers to the replacement of at least one hydrogen atom with at least one deuterium atom.
[0267] Unless otherwise indicated, compounds of the present disclosure, when a position is specifically designated as "deuterium" or "D," are understood to have an abundance of deuterium at that position that is at least 1000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 1000 times greater than the natural abundance of deuterium (i.e., at least 15% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 2000 times greater than the natural abundance of deuterium (i.e., at least 30% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3000 times greater than the natural abundance of deuterium (i.e., at least 45% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3340 times greater than the natural abundance of deuterium (i.e., at least 50.1% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 3500 times greater than the natural abundance of deuterium (i.e., at least 52.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4000 times greater than the natural abundance of deuterium (i.e., at least 60% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 4500 times greater than the natural abundance of deuterium (i.e., at least 67.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5000 times greater than the natural abundance of deuterium (i.e., at least 75% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 5500 times greater than the natural abundance of deuterium (i.e., at least 82.5% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6000 times greater than the natural abundance of deuterium (i.e., at least 90% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6333.3 times greater than the natural abundance of deuterium (i.e., at least 95% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6466.7 times greater than the natural abundance of deuterium (i.e., at least 97% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6600 times greater than the natural abundance of deuterium (i.e., at least 99% deuterium incorporation). In some embodiments, the abundance of deuterium for each designated deuterium atom is at least 6633.3 times greater than the natural abundance of deuterium (i.e., at least 99.5% deuterium incorporation). Those skilled in the art will be able to synthesize deuterated compounds with reference to the relevant literature. Commercially available deuterated starting materials can be used in the preparation of deuterated compounds, or they can be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated borane in tetrahydrofuran, deuterated lithium aluminum hydride, deuterated iodoethane, and deuterated iodomethane.
[0268] The terms "about" and "approximately" refer to values within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how it is measured or determined (i.e., the limits of the measurement system). For example, "about" can mean within 1 or more than 1 standard deviation. Alternatively, "about" or "substantially comprise" can mean a range of up to 20%, such as between 1% and 15%, between 1% and 10%, between 1% and 5%, between 0.5% and 5%, between 0.5% and 1%, and in this disclosure, each instance of a number or numerical range preceded by the term "about" also includes embodiments of the given number. Unless otherwise stated, when a specific value appears in the present application and claims, the meaning of "about" or "substantially comprise" should be assumed to be within an acceptable error range for that specific value.
[0269] The present disclosure incorporates the full texts of WO2022028462A, WO2023274395A, WO2023208023A, and WO2023109940A.
[0270] Explanation of terms
[0271] In order to make the present disclosure more easily understood, some technical and scientific terms are specifically defined below. Unless otherwise clearly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present disclosure belongs.
[0272] Unless otherwise specified, the terms "apolipoprotein (a) gene," Apo(a) gene, LPA, and Lp(a) are used interchangeably herein. LPA includes, but is not limited to, human LPA, cynomolgus monkey LPA, mouse LPA, and rat LPA. Their amino acid and complete coding sequences, as well as their mRNA sequences, are readily available using publicly available databases, such as GenBank, UniProt, OMIM, and the Macaca mulatta genome project website.
[0273] The term "target sequence" refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during LPA transcription, including mRNAs that are processed as the primary transcription product. The targeted portion of the target sequence should be sufficiently long to serve as a substrate for iRNA-directed cleavage. In one embodiment, the target sequence is within the protein-coding region of LPA.
[0274] As used herein, the sense strand of a dsRNA (also referred to as SS, SS strand, or positive strand) refers to a strand comprising a sequence that is identical or substantially identical to a target mRNA sequence; the antisense strand of a dsRNA (also referred to as AS or AS strand) refers to a strand having a sequence that is at least partially complementary to a target mRNA sequence.
[0275] In the context of describing the sense strand of a dsRNA described herein, the term "at least 17 consecutive nucleotides of the nucleotide sequence of SEQ ID NO: 1 that differ by no more than 3 nucleotides" is intended to mean that the sense strand of the dsRNA described herein comprises at least 17 consecutive nucleotides as shown in SEQ ID NO: 1, or a sequence that differs by no more than 3 nucleotides, optionally by no more than 2 nucleotides, optionally by 1 nucleotide from the sense strand of at least 17 consecutive nucleotides of SEQ ID NO: 1. Optionally, the sense strand of the dsRNA described herein comprises at least 18 consecutive nucleotides of the sense strand of SEQ ID NO: 1, or a sequence that differs by no more than 3 nucleotides, optionally by no more than 2 nucleotides, optionally by 1 nucleotide from the sense strand of at least 18 consecutive nucleotides of SEQ ID NO: 1.
[0276] In the context of describing the antisense strand of the dsRNA described herein, the term "at least 19 consecutive nucleotides that differ from the antisense strand set forth in SEQ ID NO: 2 by no more than 3 nucleotides" is intended to mean at least 19 consecutive nucleotides of the antisense strand set forth in SEQ ID NO: 2 described herein, or a sequence that differs from the at least 19 consecutive nucleotides of the antisense strand set forth in SEQ ID NO: 2 by no more than 3 nucleotides, optionally by no more than 2 nucleotides, optionally by 1 nucleotide.
[0277] In this disclosure, the "5' region," also known as the "5' end," or "5' terminus" of the sense or antisense strand may be used interchangeably. For example, nucleotides 2 through 8 in the 5' region of the antisense strand may be replaced with nucleotides 2 through 8 at the 5' terminus of the antisense strand. Similarly, the "3' region," "3' terminus," and "3' terminus" of the sense or antisense strand may be used interchangeably.
[0278] Unless otherwise specified, in the context of this disclosure, "G," "C," "A," "T," and "U" represent nucleotides, including guanine, cytosine, adenine, thymidine, and uracil, respectively. A lowercase letter "m" indicates that the nucleotide immediately upstream of the letter "m" is a methoxy-modified nucleotide; a lowercase letter "f" indicates that the nucleotide immediately upstream of the letter "f" is a fluorinated nucleotide; and a lowercase letter "s" indicates that the two nucleotides immediately adjacent to the letter "s" are linked by phosphorothioate diester groups.
[0279] As used in the present disclosure, the term "2'-fluoro (2'-F) modified nucleotide" refers to a nucleotide in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by fluorine, and "non-fluorinated modified nucleotide" refers to a nucleotide or nucleotide analog in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by a non-fluorine group.
[0280] As used in the present disclosure, the term "2'-methoxy (2'-OMe) modified nucleotide" refers to a nucleotide in which the 2'-hydroxyl group of the ribose group is replaced by a methoxy group.
[0281] In the context of the present disclosure, a "nucleotide difference" between one nucleotide sequence and another nucleotide sequence refers to a change in the base type of the nucleotide at the same position in the former compared to the latter. For example, if a nucleotide base in the latter is A, and the corresponding nucleotide base at the same position in the former is U, C, G, or T, the two nucleotide sequences are considered to have a nucleotide difference at that position. In some embodiments, when a nucleotide at the original position is replaced by an abasic nucleotide or its equivalent, a nucleotide difference at that position can also be considered.
[0282] As used herein, the terms "complementary" and "reverse complement" are used interchangeably and have the meanings known to those skilled in the art, i.e., in a double-stranded nucleic acid molecule, the bases of one strand are paired with bases on the other strand in a complementary manner. In DNA, the purine base adenine is always paired with the pyrimidine base thymine (or uracil in RNA); the purine base guanine is always paired with the pyrimidine base cytosine. Each base pair consists of a purine and a pyrimidine. When adenine on one strand is always paired with thymine (or uracil) on the other strand, and guanine is always paired with cytosine, the two strands are considered to be complementary to each other, and the sequence of the strand can be inferred from the sequence of its complementary strand. Accordingly, "mismatch" is used in the art to mean that in a double-stranded nucleic acid, the bases at corresponding positions are not paired in a complementary manner.
[0283] The term "dsRNA" refers to a double-stranded RNA molecule capable of RNA interference, comprising a sense strand and an antisense strand.
[0284] The term "chemically modified" or "modification" includes all changes in a nucleotide by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.
[0285] The term "base" encompasses any known DNA and RNA base, base analogues such as purines or pyrimidines, and also includes the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogues.
[0286] The term "optionally" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "C 1-6 The term "alkyl" means that halogen or cyano may but need not be present, and the description includes both the case where the alkyl is substituted by halogen or cyano and the case where the alkyl is not substituted by halogen and cyano.
[0287] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing from 1 to 20 carbon atoms, and in some embodiments is selected from alkyl groups containing from 1 to 12 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. In some embodiments, selected from the group consisting of alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment and, in some embodiments, is selected from one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl, or carboxylate.
[0288] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy. Alkoxy may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from halogen, hydroxy, oxo, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, 3- to 7-membered cycloalkyl or 3- to 7-membered heterocycloalkyl, wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl is optionally substituted by halogen, hydroxy, nitro, cyano or amino.
[0289] The term "alkylthio" refers to -S-(alkyl), wherein alkyl is as defined above. Non-limiting examples of alkylthio include: methylthio, ethylthio, propylthio, butylthio. Alkylthio may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups, which are independently selected from C 1-6 Alkoxy, 3 to 6 membered cycloalkyl, 3 to 6 membered heterocycloalkyl, 3 to 6 membered cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 1-6 Alkylthio, 3- to 6-membered cycloalkylthio, 3- to 6-membered heterocycloalkylthio, wherein the alkoxy, cycloalkyl, heterocycloalkyl, cycloalkyloxy, heterocyclooxy, alkylthio, cycloalkylthio, heterocycloalkylthio are optionally substituted with halogen, hydroxy, cyano or amino.
[0290] The term "alkenyl" refers to a straight or branched non-aromatic hydrocarbon group containing at least one carbon-carbon double bond and having 2 to 10 carbon atoms. Up to 5 carbon-carbon double bonds may be present in such a group. For example, "C 2- C6" alkenyl is defined as an alkenyl group having 2 to 6 carbon atoms. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, and cyclohexenyl. The straight, branched, or cyclic portion of the alkenyl group may contain double bonds and may be optionally mono-, di-, tri-, tetra-, or penta-substituted at any position permitted by normal valence.
[0291] The term "alkynyl" refers to a straight or branched hydrocarbon group containing 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Up to 5 carbon-carbon triple bonds may be present. Thus, "C2-C6 alkynyl" refers to an alkynyl group having 2 to 6 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl. The straight and branched portions of the alkynyl group may contain triple bonds as allowed by normal valence and may be optionally mono-, di-, tri-, tetra-, or penta-substituted at any position allowed by normal valence.
[0292] The term "cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, in some embodiments selected from 3 to 7 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and the like; polycyclic cycloalkyls include spirocyclic, fused, and bridged cycloalkyls. Cycloalkyls may be substituted or unsubstituted, and when substituted, the substituents may be substituted at any available point of attachment, in some embodiments selected from one or more of the following groups, independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl group is optionally substituted by one or more groups selected from halogen, deuterium, hydroxy, oxo, nitro, and cyano.
[0293] The cycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. The cycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituents are in some embodiments selected from one or more of the following groups, which are independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl group is optionally substituted by one or more groups selected from halogen, deuterium, hydroxy, oxo, nitro, and cyano.
[0294] The term "heterocycloalkyl" or "heterocycle" or "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, but excluding the ring portion of -OO-, -OS- or -SS-, the remaining ring atoms are carbon. In some embodiments, it is selected from 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; in some embodiments, it is selected from 3 to 7 ring atoms. Non-limiting examples of monocyclic heterocycloalkyl groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocycloalkyl groups include spirocyclic, fused ring and bridged heterocycloalkyl groups. Non-limiting examples of "heterocycloalkyl" include: wait.
[0295] The heterocycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a heterocycloalkyl, non-limiting examples of which include:
[0296] wait.
[0297] Heterocycloalkyl may be optionally substituted or unsubstituted. When substituted, the substituents are, in some embodiments, selected from one or more of the following groups, which are independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl group is optionally substituted by one or more groups selected from halogen, deuterium, hydroxy, oxo, nitro, and cyano.
[0298] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, in some embodiments selected from 6- to 12-membered, such as phenyl and naphthyl. The aryl ring may be fused to a heteroaryl, heterocycloalkyl, or cycloalkyl ring, wherein the ring attached to the parent structure is the aryl ring, non-limiting examples of which include:
[0299] The aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate, preferably phenyl.
[0300] The term "fused aryl" may be an unsaturated aromatic fused ring structure containing 8-14 ring atoms formed by two or more cyclic structures sharing two adjacent atoms, preferably 8-12 ring atoms. For example, it includes all unsaturated fused aryl rings, such as naphthalene, phenanthrene, etc., and also includes partially saturated fused aryl rings, such as benzo 3-8 membered saturated monocyclic cycloalkyl and benzo 3-8 membered partially saturated monocyclic cycloalkyl. "Fused aromatic ring" refers to the ring system in the fused aryl ring. Specific examples of fused aryl rings include 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, etc.
[0301] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl group is preferably 5 to 12 members, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridinyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl or thiazolyl. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is the heteroaryl ring. "Heteroaromatic ring" refers to the ring system in a heteroaryl group. Non-limiting examples of heteroaryl groups include:
[0302] Heteroaryl groups may be optionally substituted or unsubstituted. When substituted, the substituents are, in some embodiments, selected from one or more of the following groups, which are independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano, C 1- 6 alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, C 3-6 Cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C3-8 The cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl is optionally substituted by one or more groups selected from halogen, deuterium, hydroxy, oxo, nitro, cyano.
[0303] The term "alkylamino" refers to a group having the structure -NH(C1-C12 alkyl).
[0304] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0305] The term "hydroxy" refers to an -OH group.
[0306] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0307] The term "haloalkyl" refers to an alkyl group substituted with a halogen, wherein alkyl is as defined above.
[0308] The term "haloalkoxy" refers to an alkoxy group substituted with a halogen, wherein alkoxy is as defined above.
[0309] The term "cyano" refers to -CN.
[0310] The term "nitro" refers to -NO2.
[0311] The term "oxo" refers to a =0 group, eg, a carbon atom connected to an oxygen atom via a double bond, where a ketone or aldehyde group is formed.
[0312] The term "amino" refers to -NH2.
[0313] The term "carboxy" refers to -C(O)OH.
[0314] The terms "blunt end" or "blunt terminus" are used interchangeably to refer to a dsRNA having no unpaired nucleotides or nucleotide analogs at a given terminus, i.e., no nucleotide overhangs. In most cases, a dsRNA having both termini blunt-ended will be double-stranded throughout its entire length.
[0315] In the context of the present disclosure, the phosphodiester group or the modified phosphodiester group in each modification group can be replaced by any group that can achieve the connection between it and the adjacent nucleotide, such as chemical modification in The moiety can be replaced with any group that can achieve linkage to adjacent nucleotides.
[0316] The term "linked" when referring to a connection between two molecules means that the two molecules are connected by a covalent bond or the two molecules are associated via a non-covalent bond (eg, hydrogen bond or ionic bond), including direct connection and indirect connection.
[0317] The term "directly linked" refers to a first compound or group being linked to a second compound or group without any intervening atoms or groups of atoms.
[0318] The term "indirectly linked" means that a first compound or group is linked to a second compound or group through an intermediate group, compound or molecule (eg, a linking group).
[0319] The term "substituted" means that any one or more hydrogen atoms on a designated atom (typically a carbon, oxygen, and nitrogen atom) are replaced by any group as defined herein, provided that the normal valence of the designated atom is not exceeded and the substitution produces a stable compound. Non-limiting examples of substituents include C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, hydroxyl, oxo, carboxyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, ketone, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, or halogen (e.g., F, Cl, Br, I). When a substituent is ketone or oxo (i.e., =O), then two (2) hydrogen atoms on the atom are replaced.
[0320] "Substituted by one or more..." means that the compound may be substituted by a single or multiple substituents. When substituted by multiple substituents, the substituents may be multiple identical substituents or a combination of one or more different substituents.
[0321] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.
[0322] "Pharmaceutically acceptable excipients" include, but are not limited to, any adjuvant, carrier, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that has been approved for use by humans or domestic animals.
[0323] As used herein, the term "inhibit" can be used interchangeably with "reduce", "silence", "downregulate", "suppress" and other similar terms, and includes the inhibition of any level. Inhibition can be assessed by the reduction of the absolute or relative level of one or more of these variables compared to the control level. The control level can be any type of control level used in the art, such as baseline level before administration or the level determined from a similar untreated or control (such as only buffer control or inert agent control) treated subject, cell, or sample. For example, mRNA remaining expression can be used to characterize the degree of inhibition of dsRNA to target gene expression, such as mRNA remaining expression being not higher than 99%, not higher than 95%, not higher than 90%, not higher than 85%, not higher than 80%, not higher than 75%, not higher than 70%, not higher than 65%, not higher than 60%, not higher than 55%, not higher than 50%, not higher than 45%, not higher than 40%, not higher than 35%, not higher than 30%, not higher than 25%, not higher than 20%, not higher than 15%, or not higher than 10%. The inhibition rate of target gene expression can be measured using The Luciferase Assay System measures the chemiluminescence values of Firefly and Renilla, respectively, and calculates the relative value (Ratio = Ren / Fir). The inhibition rate (%) is calculated as 1 - (Ratio + siRNA / Ratio reporter only) * 100%. For purposes of this disclosure, the remaining mRNA expression ratio (or remaining activity %) is calculated as 100% - inhibition rate (%).
[0324] Unless otherwise specified, the "compound", "ligand", "nucleic acid ligand conjugate", "dsRNA conjugate", "nucleic acid", "conjugate", "chemical modification", "targeting ligand", "dsRNA", and "RNAi" of the present disclosure can independently exist in the form of a salt, a mixed salt, or a non-salt (e.g., a free acid or a free base). When present in the form of a salt or a mixed salt, it can be a pharmaceutically acceptable salt.
[0325] The term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0326] "Pharmaceutically acceptable acid addition salts" refer to salts formed with inorganic or organic acids that retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, and phosphates; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, octanoates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamate, pyroglutamate, aspartate, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbate, salicylates, 4-aminosalicylates, and naphthalene disulfonates. These salts can be prepared by methods known in the art.
[0327] "Pharmaceutically acceptable base addition salts" refer to salts formed with inorganic or organic bases that retain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts, with sodium salts being preferred. Salts derived from organic bases include, but are not limited to, following salts: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0328] An "effective amount" or "effective dose" encompasses an amount sufficient to ameliorate or prevent the symptoms or signs of a medical condition. An effective amount also means an amount sufficient to permit or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects.
[0329] As used herein, "subject," "patient," "subject," or "individual" are used interchangeably and include humans or non-human animals, such as mammals, eg, humans or monkeys.
[0330] The ordinal numbers "first", "second", etc. in the present disclosure are not intended to limit the order or hierarchy, but are only used to distinguish different features, molecules, steps, components, elements, etc.
[0331] The dsRNA provided herein can be obtained by conventional preparation methods in the art (e.g., solid-phase synthesis and liquid-phase synthesis methods). Solid-phase synthesis is commercially available on a custom basis. Modified nucleotide groups can be introduced into the dsRNA disclosed herein by using correspondingly modified nucleoside monomers. Methods for preparing correspondingly modified nucleoside monomers and methods for introducing modified nucleotide groups into dsRNA are also well known to those skilled in the art.
[0332] Some abbreviations used in this disclosure are defined as follows:
[0333] DMF: dimethylformamide;
[0334] DIPEA: N-ethyldiisopropylamine;
[0335] HBTU: benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate;
[0336] DMAP: 4-dimethylaminopyridine;
[0337] NMI: N-methylimidazole. BRIEF DESCRIPTION OF THE DRAWINGS
[0338] Figure 1A shows the ratio of serum Lp(a) concentrations of TJR101079 and TRD007790 on day 28 after administration relative to that before administration.
[0339] Figure 1B shows the ratio of serum Lp(a) concentrations of TJR101079 and TJR102134 on day 28 after administration relative to that before administration.
[0340] Figure 1C shows the ratio of serum Lp(a) concentrations of TJR101079 and TJR102136 on day 28 after administration relative to that before administration. DETAILED DESCRIPTION
[0341] The present disclosure is further described below with reference to the following examples, but these examples are not intended to limit the scope of this disclosure. Experimental methods in the examples disclosed herein, where specific conditions are not specified, were generally performed under conventional conditions or as recommended by the raw material or commercial manufacturer. Reagents whose sources are not specified can be obtained from any molecular biology reagent supplier of a quality / purity suitable for molecular biology applications.
[0342] Example 1: Chemical modification
[0343] (-)hmpNA(A)
[0344] The preparation method of (-)hmpNA(A) was carried out with reference to WO2022028462A. The absolute configuration of (-)hmpNA(A) is (R)-hmpNA(A).
[0345] Example 2: Preparation of NAG0052, L96, and NAG25
[0346] NAG0052 as shown in the above structural formula was prepared according to the method described in patent application WO2023274395A;
[0347] L96 as shown in the above structural formula was prepared according to the method described in patent application WO2014025805A;
[0348] NAG25 as shown in the above structural formula was prepared according to the method of patent application WO2017156012A.
[0349] Example 3: Preparation of deuterated 5'-terminal chemically modified phosphoramidites
[0350] first step
[0351] 1-((6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilaneoctan-8-yl)pyrimidine-2,4(1H,3H)-dione A1-2
[0352] Under a nitrogen atmosphere, commercially available compound A1-1 (100 g, 409 mmol) was dissolved in pyridine (1000 mL). 1,3-Dichloro-1,1,3,3-tetraisopropyldimethylsilyl ether (TIPDSiCl2) (135.6 g, 430.0 mmol) was added at 0°C, and the mixture was reacted at 20°C for 18 hours. The reaction solution was extracted with ethyl acetate (1500 mL) and water (1000 mL). The organic phase was washed three times with saturated brine (1000 mL x 3), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (petroleum ether:ethyl acetate = 2:1) to obtain compound A1-2 (185 g, 380 mmol, 92.8% yield).
[0353] Step 2
[0354] 3-((Benzyloxy)methyl)-1-((6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-][1,3,5,2,4]trioxadisilocan-8-yl)pyrimidine-2,4(1H,3H)-dione A1-3
[0355] Compound A1-2 (185 g, 380.1 mmol) was dissolved in N,N-dimethylformamide (1850 mL), followed by the addition of benzyl chloromethyl ether (BOMCl) (89.29 g, 570.1 mmol) and 1,8-diazabicycloundec-7-ene (DBU) (115.7 g, 760.2 mmol). The mixture was reacted at 20°C for 3 hours. The reaction solution was extracted with ethyl acetate (3000 mL) and water (3000 mL). The organic phase was washed three times with saturated brine (2000 mL x 3), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (petroleum ether:ethyl acetate = 3:1) to obtain compound A1-3 (the target compound, 172 g, 275.6 mmol, 72.5% yield).
[0356] Step 3
[0357] 3-((Benzyloxy)methyl)-1-((6aR,8R,9R,9aR)-2,2,4,4-tetraisopropyl-9-(methoxy-d3)tetrahydro-6H-furo[3,2-][1,3,5,2,4]trioxadisilocan-8-yl)pyrimidine-2,4(1H,3H)-dione A1-4
[0358] Compound A1-3 (150 g, 247.2 mmol) was dissolved in acetonitrile (300 mL), and CD3I (107.5 g, 741.5 mmol) and silver oxide (114.5 g, 494.3 mmol) were added. The mixture was reacted at 55°C for 24 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain crude compound A1-4 (the target compound, 125 g, 200.3 mmol, 81% yield).
[0359] Step 4
[0360] 3-((Benzyloxy)methyl)-1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(methoxy-d3)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione A1-5
[0361] Compound A1-4 (125 g, 200 mmol) was dissolved in tetrahydrofuran (1250 mL), and pyridine hydrofluoride (158.8 g, 1.60 mol) was added. The mixture was allowed to react at 25°C for 18 hours. The reaction solution was extracted with ethyl acetate (1000 mL) and water (1000 mL). The organic phase was washed once with saturated brine (1000 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography (dichloromethane:methanol = 20:1) to obtain compound A1-5 (the target compound, 59 g, 154.7 mmol, 77% yield).
[0362] Step 5
[0363] (2R,3R,4R,5R)-5-(3-((Benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(methoxy-d3)tetrahydrofuran-3-yl benzoate A1-6
[0364] Compound A1-5 (59 g, 154.7 mmol) was dissolved in pyridine (590 mL), and tert-butyldimethylsilyl chloride (TBSCl) (93.2 g, 618 mmol) was added. The reaction was allowed to proceed at 25°C for 18 hours. Benzoyl chloride (32.62 g, 232.0 mmol) was then added, and the reaction was continued at 25°C for 3 hours. The reaction solution was extracted with ethyl acetate (1000 mL) and water (1000 mL). The organic phase was washed twice with saturated brine (1000 mL x 2), dried over anhydrous magnesium sulfate, concentrated, and purified by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain compound A1-6 (the target compound, 60.0 g, 100.3 mmol, 64.6% yield).
[0365] Step 6
[0366] (2R,3R,4R,5R)-5-(3-((Benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-hydroxymethyl-4-(methoxy-d3)tetrahydrofuran-3-yl benzoate A1-7
[0367] Compound A1-6 (60.0 g, 100.3 mmol) was dissolved in methanol (600 mL) at 0°C, and acetyl chloride (10.21 g, 130.1 mmol) was added. The mixture was allowed to react at 20°C for 2 hours. Silver carbonate was then added, and the mixture was stirred at 20°C for 1 hour. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain compound A1-7 (46.0 g, 94.7 mmol, 94.7% yield).
[0368] Step 7
[0369] (2S,3S,4R,5R)-3-(Benzyloxy)-5-(3-((Benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-(methoxy-d3)tetrahydrofuran-2-carboxylic acid A1-8
[0370] Compound A1-7 (46.0 g, 94.75 mmol) and 4-carbonyl-tetramethylpiperidinyl oxide (TEMPO) (6.95 g, 44.49 mmol) were dissolved in CH3CN (230 mL) and H2O (230 mL), and 5(6)-amino-1-(4-aminophenyl)-1,3,3-trimethylindane (PIDA) (67.14 g, 208.4 mmol) was added. The mixture was reacted at 25°C for 18 hours. Ethyl acetate (500 mL) and water (300 mL) were added to the reaction solution for extraction. The organic phase was dried over anhydrous sodium sulfate and concentrated. The organic phase was purified by column chromatography (dichloromethane:methanol = 10:1) and concentrated under reduced pressure to obtain compound A1-8 (the target compound, 43.0 g, 86 mmol, 90% yield).
[0371] Step 8
[0372] (3S,4R,5R)-2-Acetoxy-5-(3-((benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-(methoxy-d3)tetrahydrofuran-3-ylbenzoate A1-9
[0373] Compound A1-8 (5 g, 10.0 mmol) was added to a dry flask, purged with argon, and then N, N-dimethylformamide (50 mL) was added. Pyridine (8 mL, 100 mmol) and lead acetate (9.7 mL, 50 mmol) were added in sequence. The reactants were protected from light and stirred at room temperature for 48 hours. The reaction was quenched with water (200 mL) and diluted with ethyl acetate (200 mL). The resulting suspension was filtered through a celite pad. The solid was rinsed with ethyl acetate. The organic layer was separated and concentrated in vacuo. The crude product was purified on a C18 reverse column to obtain the title product A1-9 (1.5 g, yield: 29%) as an α / β mixture.
[0374] MS (ESI): m / z = 514.2 [M+H] + .
[0375] Step 9
[0376] (3S,4R,5R)-5-(3-((Benzyloxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-((diethoxyphosphoryl)methoxy)-4-(methoxy-d3)tetrahydrofuran-3-ylbenzoate A1-10
[0377] Under an argon atmosphere, diethyl (hydroxymethyl) phosphonate (2.5 g, 156.7 mmol) and boron trifluoride diethyl etherate (5.7 mL, 43.8 mmol) were added to a solution of compound A1-9 (1.5 g, 2.9 mmol) in anhydrous dichloromethane (15 mL). The reactant was stirred at room temperature for 16 hours. The reactant was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified on a C18 reverse column to obtain title compound A1-10 (1 g, 55% yield).
[0378] MS (ESI): m / z = 622.3 [M+H] + .
[0379] Step 10
[0380] (3S,4R,5R)-2-((diethoxyphosphoryl)methoxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-(methoxy-d3)tetrahydrofuran-3-ylbenzoate A1-11
[0381] A solution of compound A1-10 (1 g, 14.6 mmol) in TFA (5 mL) was stirred at 80° C. for 30 minutes and then concentrated in vacuo to afford the title compound A1-11 (1 g, crude product), which was used directly in the next step.
[0382] MS (ESI): m / z = 502.3 [M+H] + .
[0383] Step 11
[0384] Diethyl ((((3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-(methoxy-d3)tetrahydrofuran-2-yl)oxy)methyl)phosphonate A1-12
[0385] A solution of compound A1-11 (1 g, 2.0 mmol) in ammonia methanol solution (7 N, 10 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo. The crude product was purified on a C18 reverse column to give the title compound A1-12 (300 mg, yield: 38%).
[0386] MS (ESI): m / z = 398.2 [M+H] + .
[0387] Step 12
[0388] 2-Cyanoethyl((2R,3S,4R,5R)-2-((diethoxyphosphoryl)methoxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-(methoxy-d3)tetrahydrofuran-3-yl)diisopropylphosphoramidite A1
[0389] DIPEA (58 mg, 0.45 mmol) was added to a solution of compound A1-12 (100 mg, 0.252 mmol) in anhydrous dichloromethane (2 mL), followed by the addition of 3-[chloro-(diisopropylamino)phosphoalkyl]oxypropionitrile (83 mg, 0.35 mmol). The reaction mixture was stirred at room temperature for 2 hours and then quenched with MeOH. The reaction mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate, water and brine. The organic layer was concentrated in vacuo. The crude product was purified on a C18 reverse column to give phosphoramidite monomer A1 (80 mg, yield: 53%).
[0390] MS (ESI): m / z = 596.0 [MH] + .
[0391] 1 H NMR(400MHz,CD3OD)δ7.74-7.70(m,1H),6.33-6.30(m,1H),5.84-5.82(m,1H),5.25-5.18(m,1H), 4.51-4.44(m,1H),4.27-3.67(m,11H),2.82-2.79(m,2H),1.41-1.36(m,6H),1.29-1.23(m,12H).
[0392] 31 P NMR (400MHz, CD3OD) δ151.95, 150.57, 21.29.
[0393] Example 4: Synthesis of dsRNA with a deuterated chemical modification at the 5' end
[0394] The synthesis of dsRNA is the same as the conventional phosphoramidite solid phase synthesis method. When synthesizing the terminal modified nucleotide of the antisense strand, the phosphoramidite monomer A1 synthesized in Example 3 is used at the corresponding position.
[0395] The synthesis process is briefly described as follows: Nucleoside phosphoramidite monomers were ligated one by one on a Dr. Oligo 48 synthesizer (Biolytic) starting with the Universal CPG vector according to the synthesis protocol. Except for the nucleoside phosphoramidite monomer A1 described in Example 3, the remaining nucleoside monomer starting materials, such as 2'-F RNA and 2'-O-methyl RNA, were purchased from Shanghai Zhaowei or Suzhou Jima. 5-Ethylthio-1H-tetrazole (ETT) was used as an activator (0.6 M in acetonitrile), and a 0.22 M solution of PADS in a 1:1 volume ratio of acetonitrile and collidine (Suzhou Kelema) was used as a sulfurization reagent to introduce phosphorothioates at specific positions. An iodine pyridine / water solution (Kelema) was used as an oxidant to introduce phosphoroxoates at specific positions.
[0396] After solid-phase synthesis, some embodiments require the use of TMSI to remove the 5'-terminal protecting group. For example, after solid-phase synthesis using phosphoramidite monomer A1, the crude oligoribonucleotide is suspended in anhydrous acetonitrile, TMSI is added at room temperature, and the ethyl group (Et) in the oligoribonucleotide is removed after thorough stirring to obtain an oligoribonucleotide bearing NA0127. The oligoribonucleotide is then further cleaved from the solid support using a 3:1 solution of 28% ammonia and ethanol at 50°C for 16 hours. The mixture is then centrifuged, and the supernatant is transferred to another centrifuge tube, concentrated and evaporated to dryness, and purified using C18 reversed-phase chromatography with a mobile phase of 0.1 M TEAA and acetonitrile. DMTr is removed using a 3% trifluoroacetic acid solution. The target oligonucleotide is collected, lyophilized, identified as the target product by LC-MS, and quantified by UV (260 nm).
[0397] The obtained single-stranded oligonucleotides were annealed according to complementary pairing in an equal molar ratio, and the resulting dsRNA was dissolved in 1× PBS and adjusted to the required concentration for the experiment.
[0398] The sequences of the sense and antisense chains with 5'-terminal chemical modifications containing deuteration, 2'-fluoro, 2'-methoxy, etc. are detailed in Tables 1 and 2.
[0399] Example 5: Synthesis of dsRNA conjugates
[0400] 1. Make your own resin with a carrier
[0401] The carboxylic acid-containing compound NAG0052 (157 mg, 0.062 mmol) was dissolved in anhydrous DMF (3 mL). After complete dissolution, anhydrous acetonitrile (4 mL), DIEA (0.03 mL, 0.154 mmol, 2.5 eq), and HBTU (35 mg, 0.093 mmol, 1.5 eq) were added sequentially. After the reaction mixture was thoroughly mixed, macroporous amine methyl resin (476 mg, blank loading 0.41 mmol / g, target loading 0.1 mmol / g) was added. The reaction mixture was shaken overnight on a shaker (temperature: 25°C, speed: 200 rpm). The reaction mixture was filtered, and the filter cake was washed with DCM and anhydrous acetonitrile, respectively. The solid was collected and dried under vacuum overnight.
[0402] The solid from the previous step was dispersed in anhydrous acetonitrile (5 mL), and pyridine (0.18 mL), DMAP (3 mg), NMI (0.12 mL), and CapB1 (2.68 mL) were added sequentially. The reaction mixture was shaken on a shaker (temperature: 25°C, speed: 200 rpm) for 2 hours. The reaction mixture was filtered, and the filter cake was washed with anhydrous acetonitrile. The solid was collected and vacuum dried overnight to obtain a resin with a support. The loading was determined to be 0.1 mmol / g.
[0403] 2. Using NAG0052 already attached to the resin, use the resin as a starting point to link nucleoside monomers one by one in the 3'-5' direction according to the nucleotide sequence. Each linking step involves four steps: deprotection, coupling, capping, and oxidation or sulfurization. These steps are standard in the art.
[0404] Compound NAG0052 was linked to the sequence via solid-phase synthesis. After aminolysis, some functional groups in NAG0052 were removed, resulting in NAG0052'. 3. Substituting L96 for NAG0052, the conjugates were synthesized according to the above steps. L96 was prepared according to the method described in patent application WO2014025805A.
[0405] The prepared dsRNA conjugates had the sense and antisense strands shown in Tables 1 and 2.
[0406] The positive control dsRNA conjugate TRD007790 was prepared according to the method described in patent application WO2017059223A.
[0407] Table 1. List of dsRNAs
[0408] Table 2. Sense and antisense strands of dsRNA conjugates
[0409] Among them, the capital letters G, A, C, and U represent nucleotides containing guanine, adenine, cytosine, and uracil, respectively; the lowercase letter m represents a 2'-methoxy modification; the lowercase letter f represents a 2'-fluoro modification; and the lowercase letter s represents a phosphorothioate diester linkage between the two nucleotides adjacent to the letter s.
[0410] (-)hmpNA(A)
[0411] The structure of NAG0052' is:
[0412] The structure of L96' is:
[0413] The structure of NAG25s' is:
[0414] NA0127, NA0149 and InvdA respectively represent:
[0415] Among them, the method of introducing NA0127 into dsRNA is as described in Example 4, the synthetic method of introducing NA0149 into dsRNA is referred to US20190177729A; the synthetic method of introducing InvdA into dsRNA is referred to WO2017059223A.
[0416] Table 3. Naked sequences corresponding to the sense and antisense strands of dsRNA conjugates
[0417] Example 6: Design of human LPA dsRNA
[0418] Human LPA (NM_005577.3) was used as the target gene, and 19 / 21 nt dsRNA was designed to meet the general rules for active dsRNA. The unmodified sense and antisense strand sequences are detailed in Tables 4 and 5.
[0419] Table 4. Unmodified sense and antisense strands of human LPA dsRNA
[0420] Table 5. Unmodified sense and antisense strands of human LPA dsRNA (control group)
[0421] Example 7: On-target activity of dsRNA conjugate psiCHECK 9 concentration points
[0422] In vitro molecular level simulation on-target activity screening of dsRNA / dsRNA conjugates was performed using 9 concentration gradients in HEK293A cells.
[0423] HEK293A cells were cultured in DMEM high glucose medium containing 10% fetal bovine serum at 37°C and 5% CO2. 24 h before transfection, HEK293A cells were seeded in 96-well plates at a seeding density of 8 × 10 cells per well. 3 cells, 100 μL culture medium per well.
[0424] According to the instructions, dsRNA conjugates and corresponding plasmids were co-transfected into cells using Lipofectamine 2000 (ThermoFisher, 11668019), using 0.3 μL Lipofectamine 2000 per well. The plasmid transfection amount was 40 ng per well. For the target sequence plasmid, 9 concentration points were set for the dsRNA / dsRNA conjugate, with the highest concentration point having a final concentration of 20 nM, 3-fold gradient dilution, 20 nM, 6.666666667 nM, 2.222222222 nM, 0.740740741 nM, 0.24691358 nM, 0.082304527 nM, 0.027434842 nM, 0.009144947 nM, 0.003048316 nM. 24 h after transfection, the target level was detected using the Dual-Luciferase Reporter Assay System (Promega, E2940).
[0425] The results are shown in Table 6.
[0426] Table 6. dsRNA / dsRNA conjugate activity results at 9 points in the psi-Check system
[0427] Example 8: Inhibition of human LPA in primary human hepatocytes (PHH) by dsRNA - Inhibitory activity at 7 concentration points
[0428] dsRNA sequences were screened for PHH activity in primary human hepatocytes (PHH) using a 7-point concentration gradient. Each dsRNA sample was transfected at a concentration of 20 nM, with 5-fold gradient dilution and 7 concentration points.
[0429] PHH were frozen in liquid nitrogen. 24 h before transfection, primary human hepatocytes (PHH) were revived and seeded into 96-well plates at a seeding density of 3 × 104 cells per well in 80 μL of culture medium per well.
[0430] Lipofectamine RNAi MAX (ThermoFisher, 13778150) was used for dsRNA transfection according to the product manual. The final concentration of dsRNA transfection was 20 nM, 4 nM, 0.8 nM, 0.16 nM, 0.032 nM, 0.0064 nM, and 0.00128 nM. After 24 hours of treatment, total RNA was extracted from cells using a high-throughput RNA extraction kit, followed by reverse transcription and quantitative real-time PCR. Human LPA mRNA levels were measured and corrected for GAPDH levels.
[0431] Among them, in the quantitative real-time PCR detection, a probe Q-PCR detection experiment was used, and its primer information is shown in Tables 7 and 8.
[0432] After the Taqman probe Q-PCR test experiment is completed, the corresponding Ct value is obtained according to the threshold automatically set by the system. The expression of a certain gene can be relatively quantified by comparing the Ct values: Comparative Ct refers to calculating the gene expression difference by the difference between the Ct value and the internal reference gene, also known as 2-△△Ct, △△Ct = [(Ct experimental group target gene - Ct experimental group internal reference) - (Ct control group target gene - Ct control group internal reference)].
[0433] Inhibition rate (%) = (1-remaining expression level of target gene)*100%.
[0434] The results are expressed as the percentage of human LPA mRNA expression remaining relative to that of cells treated with control dsRNA. The IC50 results of the inhibition rate are shown in Table 9.
[0435] The results showed that TJR100373 had significantly superior activity compared with TJR100374 to TJR100380, indicating that the target gene fragment targeted by TJR100373 was more suitable as a target.
[0436] Table 7. Taqman LPA probe primer information
[0437] Table 8. Taqman GAPDH probe primer information
[0438] Table 9. Multiple-dose inhibitory activity of dsRNA against human LPA in primary human hepatocytes (PHH)
[0439] Example 9: Determination of in vivo activity of dsRNA conjugates in humanized mice (hu-Lp(a))
[0440] The humanized mice (hu-Lp(a)) used in this example were constructed by Shanghai Tuojie Biotechnology Co., Ltd. on behalf of Saiye (Suzhou) Biotechnology Co., Ltd.
[0441] According to the serum Lp (a) protein content, the mice were evenly divided into groups, with 6 mice in each group (2 males and 4 females), for a total of 4 groups. They were given normal saline, positive control TRD007790, and dsRNA conjugate TJR101079 disclosed herein by subcutaneous injection. The dosage was 3 mg / kg, and the administration volume was 10 μL / g. 40 μL of serum was collected before administration on the day of administration, and the measured serum Lp (a) concentration was used as the basic data. The dosing diary was day 1 (D1), day 8 (D8), day 29 (D29), day 57 (D57), day 85 (D85), and day 99 (D99) after administration. 40 μL of serum was collected each time, and the serum Lp (a) protein content was determined using the Abbott Ci4100 fully automatic biochemical immunoassay, and the inhibition of dsRNA conjugate on serum Lp (a) protein expression in humanized mice (hu-Lp (a)) was calculated. The ratio of serum Lp(a) protein to blank after normalization of each drug administration group to the blank control group was calculated, and the results are recorded in Table 10. One-way ANOVA was used to analyze the statistical data of each group relative to the blank drug administration group.
[0442] According to the results in Table 10, on the 99th day, there was no statistical difference between the blank control group and the positive control group TRD007790, while TJR101079 still showed obvious inhibition of Lp(a) protein expression, with a statistically significant p<0.01, indicating that on the 99th day, TRD007790 had no obvious inhibitory activity, while TJR101079 still had significant inhibitory activity.
[0443] This indicates that the dsRNA conjugate TJR101079 disclosed in the present invention has an excellent long-term inhibitory effect on Lp(a) protein expression.
[0444] Table 10. Serum Lp(a) protein concentrations in humanized mice (hu-Lp(a))
[0445] In Table 10, * indicates p≤0.05; ** indicates p<0.01; *** indicates p<0.001; **** indicates p<0.0001.
[0446] Example 10: Determination of in vivo activity of dsRNA conjugates in humanized mice (hu-Lp(a))
[0447] The humanized mice (hu-Lp(a)) used in this example were constructed by Shanghai Tuojie Biotechnology Co., Ltd. on behalf of Saiye (Suzhou) Biotechnology Co., Ltd.
[0448] The mice were divided into 4 groups based on their serum Lp(a) protein levels, with 6 mice in each group. Each group was administered subcutaneously. The dsRNA conjugates TRD007790, TJR101079, TJR102134, and TJR102136 were all administered at a dose of 1 mg / kg in a volume of 10 μL / g. On the day of administration, 40 μL of serum was collected before administration, and the serum Lp(a) concentration was used as the baseline data. The dosing diary was recorded on day 1 (D1) and day 28 (D28) after administration. 40 μL of serum was collected each time, and the serum Lp(a) protein content was measured using an Abbott Ci4100 fully automatic biochemical immunoassay. The inhibitory effect of the dsRNA conjugates on serum Lp(a) protein expression in humanized mice (hu-Lp(a)) was calculated. The ratio of serum Lp(a) protein to blank after normalization of each treatment group was calculated. The results are shown in Figures 1A, 1B, and 1C. The serum Lp(a) concentration on D28 of each group was compared with the serum Lp(a) before administration to obtain the residual serum Lp(a) ratio, and the paired t test was used to perform statistical comparisons between TJR101079 and TRD007790, TJR102134, and TJR102136.
[0449] As shown in Figures 1A, 1B, and 1C, on Day 28, the ratios of serum Lp(a) in each group compared to pre-dose levels were significantly different between TJR101079 and TRD007790, TJR102134, and TJR102136. TJR101079 vs. TRD007790: "*" p<0.05; TJR101079 vs. TJR102134: "*" p<0.05; and TJR101079 vs. TJR102136: "**" p<0.01.
[0450] This shows that TJR101079 has a better effect on the long-term inhibition of Lp(a) protein expression than the control groups TRD007790, TJR102134 and TJR102136, that is, compared with the control conjugates, the dsRNA conjugates disclosed in the present invention have a significantly better effect on the long-term inhibition of Lp(a) protein expression.
Claims
1. A double-stranded ribonucleic acid (dsRNA) targeting LPA, comprising a sense strand and an antisense strand forming a double-stranded region, wherein: The naked nucleotide sequence of the sense strand comprises at least 17 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 1 by no more than 3 nucleotides; and The naked nucleotide sequence of the antisense strand comprises at least 19 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 2 by no more than 3 nucleotides; Among them, from the 5' end to the 3' end, The nucleotides at positions 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; The nucleotides at positions 2 and 14 of the antisense strand are 2'-fluoro-modified nucleotides, the nucleotides at positions 4, 6, 10, 12, 16 and 18 are independently 2'-methoxy or 2'-fluoro-modified nucleotides, and the nucleotides at the remaining positions are 2'-methoxy-modified nucleotides; The number of 2'-fluoro-modified nucleotides in the antisense strand is 2-7.
2. The dsRNA according to claim 1, wherein The naked nucleotide sequence of the sense strand comprises the nucleotide sequence shown in SEQ ID NO:1, and the naked nucleotide sequence of the antisense strand comprises the nucleotide sequence shown in SEQ ID NO:
2.
3. The dsRNA according to claim 1 or 2, wherein The nucleotide at position 7 at the 5' end of the antisense strand is a modified nucleotide, wherein: - the modified nucleotide is a 2'-methoxy modified nucleotide, or - The modified nucleotide comprises a chemical modification represented by formula (I), (I-1), (I-2) or a pharmaceutically acceptable salt thereof: Wherein, B represents the base corresponding to the 7th nucleotide at the 5' end of the antisense strand.
4. The dsRNA according to any one of claims 1 to 3, wherein The first nucleotide at the 5' end of the antisense strand is a modified nucleotide, wherein: - the modified nucleotide is a 2'-methoxy modified nucleotide, or - The modified nucleotide is a chemically modified nucleotide represented by formula (II): Wherein, B represents the base corresponding to the first nucleotide at the 5' end of the antisense strand.
5. The dsRNA according to any one of claims 1 to 4, wherein The sense strand contains the nucleotide sequence shown in the following formula: 5’-N a N a N a N a N a N a N b N b N b N a N a N a N a N a N a N a N a N a N a -3’; Among them, N a is a 2'-methoxy-modified nucleotide, N b It is a 2'-fluoro modified nucleotide.
6. The dsRNA according to any one of claims 1 to 5, wherein The antisense strand comprises a nucleotide sequence as shown in the following formula: 5’-N a ’N b ’N a ’X’N a ’X’N a ’N a ’N a ’X’N a ’X’N a ’N b ’N a ’X’N a ’X’N a ’N a ’N a ’-3’, or 5′-N a 'N b 'N a 'X'N a 'X'W' a 'N a 'X'N a 'X'N a 'N b 'N a 'X'N a 'X'N a 'N a 'N a '-3', new 5’-V’N b ’N a ’X’N a ’X’N a ’N a ’N a ’X’N a ’X’N a ’N b ’N a ’X’N a ’X’N a ’N a ’N a ’-3’; Preferably, the antisense strand comprises a nucleotide sequence as shown in the following formula: 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N b ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N b ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N b ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-N a ’N b ’N a ’N a ’N a ’N a ’W’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-V’N b ’N a ’N a ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’-3’, 5’-V’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’N b ’N a ’N b ’N a ’N a ’N a ’N a ’N a ’N a ’N a ’-3’; Where each X' is independently N a ' or N b ';N a ' is a 2'-methoxy modified nucleotide, N b ' is a 2'-fluoro modified nucleotide; W' represents a nucleotide comprising a chemical modification represented by formula (I), (Ⅰ-1), (Ⅰ-2) or a pharmaceutically acceptable salt thereof; V' represents a chemically modified nucleotide represented by formula (Ⅱ).
7. The dsRNA according to any one of claims 1 to 6, wherein At least one phosphodiester group in the sense strand and / or antisense strand is a phosphodiester group having a modified group, preferably a thiophosphate diester group.
8. The dsRNA according to claim 7, wherein The phosphorothioate diester group is present in at least one of the following positions: Between the first nucleotide and the second nucleotide at the 5' end of the sense strand; Between the second nucleotide and the third nucleotide at the 5' end of the sense strand; Between the first nucleotide and the second nucleotide at the 3' end of the sense strand; Between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; Between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and Between the second nucleotide and the third nucleotide at the 3' end of the antisense strand; Preferably, the sense strand and / or antisense strand comprises a plurality of phosphorothioate diester groups, wherein the phosphorothioate diester groups are present in: between the first nucleotide and the second nucleotide at the 5' end of the sense strand; and, between the second nucleotide and the third nucleotide at the 5' end of the sense strand; and, between the first nucleotide and the second nucleotide at the 3' end of the sense strand; and between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; and, between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; and, between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and, between the second nucleotide and the third nucleotide at the 3' end of the antisense strand; or, The sense strand and / or antisense strand comprises a plurality of phosphorothioate diester groups, wherein the phosphorothioate diester groups are present in: between the first nucleotide and the second nucleotide at the 5' end of the sense strand; and, between the second nucleotide and the third nucleotide at the 5' end of the sense strand; and, between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; and, between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; and, between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; and, Between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
9. The dsRNA of any one of claims 1 to 8, wherein The sense strand comprises the nucleotide sequence shown in SEQ ID NO:6, and the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22 to SEQ ID NO:33, and SEQ ID NO:35; or, The sense strand comprises the nucleotide sequence shown in SEQ ID NO:7, and the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NO:9 to SEQ ID NO:20, SEQ ID NO:33 to SEQ ID NO:
35.
10. A dsRNA conjugate comprising: The dsRNA of any one of claims 1 to 9, and a targeting ligand attached to a terminus of the dsRNA; Preferably, the targeting ligand is attached to the 3' end of the sense strand of the dsRNA.
11. The dsRNA conjugate of claim 10, wherein: The targeting ligand comprises at least one targeting moiety, The targeting moieties are each independently selected from the group consisting of galactose, galactosamine, N-formyl-galactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butyryl-galactosamine and N-isobutyryl-galactosamine; Preferably, the targeting moiety is N-acetyl-galactosamine; More preferably, the targeting ligand comprises three identical or different targeting moieties.
12. The dsRNA conjugate according to claim 11, wherein the targeting ligand is a compound represented by formula (III-1) or (III-2) or a pharmaceutically acceptable salt thereof, wherein: The formula (III-1) is: The formula (III-2) is:
13. The dsRNA conjugate according to any one of claims 10 to 12, wherein The ligand is linked to the dsRNA via a phosphodiester group or a phosphorothioate diester group; preferably via a phosphodiester group.
14. The dsRNA conjugate according to any one of claims 10 to 13, wherein The sense strand comprises the nucleotide sequence shown in SEQ ID NO:3, and the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22 to SEQ ID NO:33, and SEQ ID NO:35; or, The sense strand comprises the nucleotide sequence shown in SEQ ID NO:4, and the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NO:9 to SEQ ID NO:20, SEQ ID NO:33 to SEQ ID NO:35; or, The sense strand comprises the nucleotide sequence shown in SEQ ID NO:5, and the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NO:16, SEQ ID NO:20, and SEQ ID NO:
33.
15. The dsRNA conjugate according to any one of claims 10 to 14, wherein The dsRNA conjugate is selected from the following structures or pharmaceutically acceptable salts thereof: in, Af = adenine 2'-F ribonucleoside; Cf = cytosine 2'-F ribonucleoside; Uf = uracil 2'-F ribonucleoside; Gf = guanine 2'-F ribonucleoside; Am = adenine 2'-OMe ribonucleoside; Cm = cytosine 2'-OMe ribonucleoside; Gm = guanine 2'-OMe ribonucleoside; Um = uracil 2'-OMe ribonucleoside; represents the anionic form of the phosphorothioate diester group; Indicates the phosphodiester anion form; NAG0052' indicates 16. A pharmaceutical composition comprising: The dsRNA according to any one of claims 1 to 9 and / or the dsRNA conjugate according to any one of claims 10 to 15; Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
17. Use of the dsRNA according to any one of claims 1 to 9 and / or the dsRNA conjugate according to any one of claims 10 to 15 and / or the pharmaceutical composition according to claim 16 in the preparation of a drug; The drug is used for preventing and / or treating cardiovascular diseases, or The medicament is used for preventing and / or treating diseases associated with elevated levels of lipoprotein (a) and / or apolipoprotein (a); Preferably, the disease associated with elevated levels of lipoprotein(a) and / or apolipoprotein(a) is selected from: cardiovascular disease; The cardiovascular disease is selected from the group consisting of ischemic stroke, atherosclerosis, thrombosis, coronary heart disease, lower extremity arterial disease, aortic valve stenosis, myocardial infarction, coronary artery stenosis, carotid artery stenosis, femoral artery stenosis, and heart failure.
18. A method for inhibiting LPA expression, comprising administering to a subject an effective amount or an effective dose of the dsRNA according to any one of claims 1 to 9 and / or the dsRNA conjugate according to any one of claims 10 to 15 and / or the pharmaceutical composition according to claim 16.
19. A method for delivering dsRNA to the liver in vivo to inhibit LPA expression and / or replication, comprising administering to a subject an effective amount or an effective dose of the dsRNA according to any one of claims 1 to 9 and / or the dsRNA conjugate according to any one of claims 10 to 15 and / or the pharmaceutical composition according to claim 16.
20. A cell comprising the dsRNA of any one of claims 1 to 9 and / or the dsRNA conjugate of any one of claims 10 to 15 and / or the pharmaceutical composition of claim 16.
21. A kit comprising the dsRNA according to any one of claims 1 to 9 and / or the dsRNA conjugate according to any one of claims 10 to 15 and / or the pharmaceutical composition according to claim 16.
22. A method for preparing a dsRNA, a dsRNA conjugate or a pharmaceutical composition, comprising: Synthesizing the dsRNA according to any one of claims 1 to 9 and / or the dsRNA conjugate according to any one of claims 10 to 15; and / or Formulate the pharmaceutical composition of claim 16.
Citation Information
Patent Citations
4'-phosphate analogs and oligonucleotides comprising the same
US20190177729A1
Carbohydrate conjugated RNA agents and process for their preparation
WO2014025805A1
Targeting ligands for therapeutic compounds
WO2017156012A1
Modified sirna with reduced off-target activity
WO2022028462A1
LPA-targeting sirna and conjugate
WO2023109940A1
Cited By
SiRNA for targeted regulation of LPA gene expression and application thereof
CN120485189A
